Smallpox Drug Passes First Human Safety Tests
Global Security Newswire
An experimental smallpox drug successfully passed the first round of human safety testing, The Oregonian reported yesterday (see GSN, Jan. 27).
Volunteers given different doses of the drug suffered no significant side effects.
Siga Technologies Inc. is seeking federal approval for a three-week trial of daily dosing, said Chief Financial Officer Thomas Konatich
The publicly owned company has conducted animal studies in two species. One study proved that the smallpox drug protects ground squirrels from lethal does of monkeypox (Joe Rojas-Burke, The Oregonian, July 15).
An experimental smallpox drug successfully passed the first round of human safety testing, The Oregonian reported yesterday (see GSN, Jan. 27).
Volunteers given different doses of the drug suffered no significant side effects.
Siga Technologies Inc. is seeking federal approval for a three-week trial of daily dosing, said Chief Financial Officer Thomas Konatich
The publicly owned company has conducted animal studies in two species. One study proved that the smallpox drug protects ground squirrels from lethal does of monkeypox (Joe Rojas-Burke, The Oregonian, July 15).
